IsoPlexis teams with industry leaders to accelerate the development of improved detection methods that inform understanding and treatment of COVID-19 [24-March-2020] BRANFORD, Conn. and SEATTLE , March 24, 2020 /PRNewswire/ -- IsoPlexis, the leader in functional cellular proteomics, and the Institute for Systems Biology (ISB) announced a partnership mapping function
| BRANFORD, Conn. and SEATTLE, March 24, 2020 /PRNewswire/ -- Isoplexis, the leader in functional cellular proteomics, and the Institute for Systems Biology (ISB) announced a partnership mapping functional immune responses at the single cell level to study COVID-19.
Uncovering functional immune responses using IsoPlexis technologies have underpinned key breakthroughs in therapies that harness the immune system across disease areas. The data from this partnership will be released as soon as possible and made globally available to researchers combatting the disease. “Global effort and partnerships are needed to reach an accelerated understanding of COVID-19,” said James Heath, President of the Institute for Systems Biology. “Critical information from all aspects of the immune response will be key in understanding how to fight the disease and address complications. Functional phenotyping of each immune cell, using IsoPlexis’ system, will be a cornerstone of the understanding of this immune response in affected patients.” “This partnership with the ISB underpins our goal to accelerate immune understanding and medicine in COVID-19. Through our unique functional analysis of each cell, we can unlock further understanding of how COVID-19 interacts with the immune system,” said Sean Mackay, CEO and co-founder of IsoPlexis. “Cellular immune signatures based on cytokines may be key in understanding and predicting response, and also how to mitigate disease progression.” Research will be performed on immune cells from individuals who have been diagnosed with or recovered from COVID-19. IsoPlexis’ single cell functional proteomics platform will be utilized on a variety of immune cell types, including various T cells and myeloid cells to put together a map of the overall response. ABOUT ISOPLEXIS: IsoPlexis (www.isoplexis.com) is dedicated to accelerating the fight against cancer and a range of the world’s toughest diseases with its uniquely correlative, award-winning, cellular proteomics systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise and personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine and Fierce, are used globally to advance the field of immune biology and biomarkers as we generate solutions to overcome the challenges of complex diseases. ISOPLEXIS MEDIA CONTACT: Jon Chen
SOURCE IsoPlexis |
View original content to download multimedia:
